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Summary Culture of ZR-75-1 human breast cancer cells for 5 days in the absence of oestrogens (phenol
red-free medium supplemented with dextran coated charcoal stripped 5% fetal calf serum) resulted in a
slowing of growth rate and loss of progesterone receptors. Oestradiol at 10' M markedly stimulated growth
and progesterone receptor synthesis over a 5-day period. While medroxyprogesterone acetate (10-10 to 10-6 M)
inhibited growth of ZR-75-1 cells growing in complete medium, in the short-term absence of oestrogens low
concentrations were growth stimulatory. Cells deprived of oestrogens for 5 days retained sensitivity to growth
inhibition by 4-hydroxy tamoxifen. ZR-75-1 cells were also adapted to growth in the absence of oestrogens
over a 5-month period. These cells (ZR-PR-LT) failed to express binding sites characteristic of the type I
oestrogen receptor but progesterone receptor expression was at a level normally associated with oestrogen
induction. Adapted cells were growth inhibited by oestradiol, 4-hydroxy tamoxifen and medroxyprogesterone
acetate, but despite elevated progesterone receptor expression the progestin was only marginally more
inhibitory than in the parent line. Our data indicate a poor quantitative relationship between response to
progestins in vitro and progesterone receptor concentration and support previous findings that acquisition of
an oestrogen independent phenotype does not necessarily result in resistance to anti-oestrogens.
Although approximately 70% of breast cancer patients
whose primary tumours are positive for the presence of
oestrogen receptors (ER) and progesterone receptors (PGR)
respond to hormonal therapy (Clark & McGuire, 1983),
virtually all will ultimately become resistant to this treatment.
Treatment failure may be associated with a variety of
changes in tumour characteristics leading to a more malig-
nant phenotype, including the development of anti-oestrogen
resistance (Nawata et al., 1981; Bronzert et al., 1985; van den
Berg et al., 1989) and progression to oestrogen independence.
Stepwise progression from hormone dependence to
independence has been extensively investigated in rodent
mammary (Sluyser & Van Nie, 1974; Darbre & King, 1988)
and prostatic (Humphries & Isaacs, 1982) cancers. Similar
observations in human breast cancer growing in long-term
culture have only been possible since the discovery that the
pH indicator phenol red acts as a weak oestrogen (Berthois
et al., 1986). Both MCF-7 (Katzenellenbogen et al., 1987)
and ZR-75-1 (Glover et al., 1988) human breast cancer cells
respond to transfer to oestrogen and phenol red free medium
with a slowing of growth rate and loss of PGR. Growth rate
is markedly accelerated by oestradiol-17p (E2) treatment
which also induces PGR synthesis. In these short-term oest-
rogen deprived cells anti-oestrogens appear to act as partial
agonists/antagonists. Prolonged culture of MCF-7 cells under
oestrogen free conditions results in an increased rate of cell
proliferation which is unaffected by E2, although PGR syn-
thesis remains E2 dependent (Katzenellenbogen et al., 1987;
Welshons & Jordan, 1987). This adaptation to oestrogen
independent growth is also associated with an increase in ER
expression and retention of sensitivity to the antiproliferative
effects of anti-oestrogens.
In this study we have examined the response of ZR-75-1
cells to prolonged oestrogen withdrawal. We report that
adaptation of ZR-75-1 cells to oestrogen free growth results
in loss of specific binding sites for E2 characteristic of type 1
receptors and that this is accompanied by a marked elevation
of PGR levels. We also describe the effects of E2, 4-hydroxy
tamoxifen and medroxyprogesterone acetate (MPA) on cell
proliferation in short and long term oestrogen deprived cells.
Materials and methods
Cell lines
The ZR-75-l human breast cancer cell line was obtained
from Flow Laboratories (Irvine, UK). Cells were routinely
maintained in RPMI 1640 medium supplemented with 5%
fetal calf serum (FCS, Flow Laboratories or Imperial
Laboratories, Andover, Hampshire, UK), 100 IU ml-'
penicillin and 100 ig ml-' streptomycin. Cells were grown in
a 5% CO2 :air atmosphere at 37°C.
Cells were deprived of known oestrogenic stimuli by trans-
ferring them to RPMI medium lacking phenol red (Sigma
Chemical Company, Poole, Dorset, UK) and supplemented
with heat treated (53'C, h) 5% FCS stripped by dextran
coated charcoal treatment (FCSdcc). Cells grown in this
medium for 5 days before experimentation are referred to as
ZR-PR 5 days. Cells referred to as ZR-PR-LT had been
growing in oestrogen free conditions for between 5 and 18
months at the time of investigation, during which period the
phenotype remained stable.
Drugs
4-Hydroxy tamoxifen was a gift from ICI Pharmaceuticals
(Macclesfield, Cheshire, UK). MPA, diethylstilbestrol and E2
were obtained from Sigma Biochemicals (Poole, Dorset,
UK). 2,4,6,7,16,17 3H-oestradiol (E2), 3H-ORG 2058 and
unlabelled ORG 2058 were obtained from Amersham Inter-
national (Bucks., UK).
Receptor assays and drug effects on cellproliferation
ER and PGR expression was determined using a whole cell
binding assay at 37'C as previously described (van den Berg
et al., 1987). Briefly, cells were plated into 24-place microwell
dishes (Becton Dickinson, Oxford, UK) at a density of 105 or
5 x 104 per well for ER or PGR assays respectively. Binding
of radioactive ligand was determined following a I h incuba-
tion at 37°C 24 h (ER) or 5 days (PGR) later. E2 binding was
determined using 2,4,6,7,16,17 3H-E2 (Amersham Interna-
tional) as the radioactive ligand (0.1-2.8 nM) in the absence
or presence of a 200-fold excess of diethylstilbestrol. To
measure PGR, 0.1 - 1.8 nM 3H-ORG 2058 (Amersham Inter-
national) was used. Non-specific binding was determined
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in the presence of a 200-fold excess of unlabelled ligand.
Limits of detection were 10 and 15 fmol mg-' protein for
PGR and ER respectively.
The effects of continuous drug treatment on cell prolifera-
tion was assessed by growing cells in microwell dishes (well
surface area 2cm2). After trypsinisation cell numbers were
determined using a Coulter Counter Model D (Coulter Elec-
tronics, Luton, Beds., UK.).
Results
The effect ofE2 on the proliferation ofZR-75-1 cells after
short and long-term E2 withdrawal
Figure 1 shows the effect of short and long-term oestrogen
deprivation on the response of ZR-75-1 to a physiological
and pharmacological concentration of E2. Within 5 days of
transfer to oestrogen free medium proliferation of ZR-75-1
cells slowed markedly, with the doubling time extending from
approximately 2 to 8 days. E2 at 10- M, which is only
marginally growth stimulatory in the presence of phenol red
and serum associated oestrogens, significantly stimulates the
proliferation of short-term oestrogen deprived cells. E2 at
10-6M inhibits growth of both populations. ZR-75-1 cells
continued to proliferate slowly in oestrogen free medium for
three months, at which point growth virtually ceased. Over
the following 2 months a number of flasks were lost as a
result of unsuccessful attempts to subculture. Three 75cm2
flasks survived and after approximately 5 months in oestro-
gen free medium growth rate rapidly increased and the cells
took on a healthy epithelial appearance under phase contrast
microscopy. There was no evidence of selective colony
growth and cells have not been cloned. Population doubling
time for these adapted cells is indistinguishable from that of
the parent line despite being grown in phenol red-free RPMI
supplemented with 5% FCSdcc (Figure 1). While 10-6 M E2
again inhibits cell proliferation, 10-9 M E2 not only fails to
stimulate growth but is itself slightly growth inhibitory.
ER and PGR expression in short and long-term E2 deprived
ZR-75-1 cells
The effect of short and long-term deprivation of oestrogens
on ER and PGR expression in ZR-75-1 cells in shown in
Table I.
In the presence of phenol red and unstripped ZR-75-1 cells
express ER (Kd 0.62 ± 0.15 nM) and low levels of PGR (Kd
0.24 ± 0.08 nM). PGR expression increases 10-15-fold dur-
ing a 5 day exposure to 10-9 M E2. Simultaneous exposure of
ZR-75-1 cells to 10-9 M E2 and 10-9 M MPA results in only
a 2-fold increase in PGR levels. Transfer of cells to oestrogen
free medium for 5 days has no significant effect on ER
expression while PGR is no longer detectable, but can be
induced by E2 treatment. In cells adapted to growth in
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Figure 1 The effect of short and long-term oestrogen deprivation
on the proliferative response of ZR-75-1 cells to oestradiol.
Values are means ± standard errors of three determinations.
Cell number at day 0 was 5 x 104 per well. M, control; M,
10-9M E2; M
, 10-6 M E2.
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Figure 2 Specific binding of 3H-oestradiol by ZR-75-1 and ZR-
PR-LT cells (each point represents the mean of three determina-
tions). Specific binding represents total binding less non-specific
binding. 0, ZR + PR; *, ZR-PR-LT.
Table I ER and PGR expression in ZR-75-1 cells: the effect of short
and long-term E2 deprivation
ZR-PR
Receptor ZR + PR ZR-PR S days long-term
ER 214 10 189 ± 23 ND
PGR basal 81± 11 ND 1675 134
PGR 1237 133 1163 168 1443 215
+ l0-9 M E2a
PGR 169 273
+10-9 M MPAb
All values areexpressed as fmol mg- I proteinandaremeans ± s.e. of
three separate determinations, with the exception of PGR + l0-9 M
MPA. ND, not detectable. a5 days exposure to 10-9 M E2. b5 days
exposure to l0-9 M E2 plUS 10-9 M MPA (ZR + PR), or MPA alone
(LT-PR).
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Figure 3 Specific binding of 3H ORG 2058 by ZR-75-1 and
ZR-PR-LT cells (each point represents the mean of three deter-
minations). Specific binding represents total binding less non-
specific binding. 0, ZR + PR; A, ZR + PR, 5 days 10-9 M E2;
0, ZR-LT-PR.
3.5
LO
3(0-
ZR+PR ZR-PRZRP
5 Days Long term
Figure 4 The effect of short and long-term oestrogen deprivation
on the proliferative response of ZR-75-1 cells to 4-hyroxy tamox-
ifen. Values are means and standard errors of three determina-
tions. Cell number at day 0 was 5 x 104 per well. _, control;
1,10-8M 40H TAM; ~, 10-7M 40H TAM.506 H.W. VAN DEN BERG et al.
oestrogen free conditions, saturable binding of E
tic of the type 1 receptor is not observed. Withi
concentration range used, bound radioactivity
by an excess of unlabelled diethylstilbestrol is
this binding is linear, failing to demonstrate
indicative of specific binding (Figure 2). Despitl
of detectable type 1 ER ZR-PR-LT cells expre
of PGR comparable to E2 induced PGR expre
75-1 cells (Table I and Figure 3). Receptor affir
2058 was unchanged. PGR synthesis in ZR-P]
not strictly constitutive, since receptor is down
MPA treatment (Table I).
The effect ofE2 deprivation on theproliferative re
ZR-75-1 cells to 4-hydroxy tamoxifen and MPA
Proliferation of ZR-75-1 cells deprived of E2 I
slowed further during a 6-day exposure to 4-hy4
ifen (10-8 and 10-7M, Figure 4). Despite th4
detectable type 1 ER ZR-PR-LT remain sen
anti-proliferative effects of the anti-oestroge
while the anti-proliferative effects of anti-oestr4
reversed by E2 in ZR-75-1 cells (van den Berg et
(10- M) not only fails to reverse growth inh
hydroxy tamoxifen in ZR-PR-LT cells but ha:
imately additive anti-proliferative effect (Figur
The effect of E2 deprivation on the anti-prolif
of MPA in ZR-75-1 cells is complex (Figur
presence of phenol red and complete serum, M.
inhibitory at all concentrations tested. In co
(10-8 to 10l0 M) significantly stimulates prolifei
75-1 cells deprived of oestrogens for 5 days. Hi
trations are without effect. Adaptation to oestro
ditions is associated with a return to MPA in
10.0
0F)
0
x
1. -_
E
C:
-)
0.1
0 3 6
Treatment time (days)
Figure 5 The effect of 4-hydroxy tamoxifen on the
of ZR-PR-LT cells in the presence and absence of
Values are means of three determinations. 0, contrn
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Figure 6 The effect of short and long-term oestroge
on the proliferative response of ZR-75-1 cells to MP
means and standard errors of three determinations.
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inhibition. Although ZT-PR-LT cells consistently showed a
slightly greater sensitivity to MPA compared to the parent
line, this difference rarely reached significance.
Discussion
ssion in ZR- We have confirmed that short-term oestrogen deprivation
nity for ORG results in a reduction in the proliferative rate of E2 sensitive
R-LT cells is human breast cancer cells in long-term culture and that
regulated by growth rate can be increased (Figure 1) and PGR expression
induced (Table I) by E2 exposure (Berthois et al., 1986). We
also confirm that 4-hydroxy tamoxifen inhibits proliferation
further (Glover et al., 1988). Partial agonist effects are only
sponse of observed at lower concentrations than those used in this
study (Katzenellenbogen et al., 1987).
for 5 days is Adaptation of ZR-75-1 cells to growth in the apparent
droxy tamox- absence of oestrogens occured over a very similar time period
e absence of to that reported for MCF-7 cells (Katzenellenbogen et al.,
sitive to the 1987). However, changes in ER and PGR expression
n. However, associated with adaptation in ZR-75-1 cells differ markedly.
ogens can be Specific E2 binding characteristic of type 1 receptors is
t al., 1989) E2 absent, although bound radioactivity displaceable by an
,ibition by 4- excess ofdiethylstilbestrol is evident (Figure 2). The nature of
s an approx- these binding sites is unknown at present but they may
e 5). represent partial occupation of low affinity, high capacity
erative effects type 2 ER (Panko et al., 1981).
*e 6). In the Despite the apparent absence of type 1 ER and routine
PA is growth maintanance in medium lacking oestrogenic activity, PGR
pntrast, MPA expression by ZR-PR-LT cells is at a level normally
ration of ZR- associated with E2 induction (Table I and Figure 3). A
igher concen- variant of the T47-D human breast cancer cell line has been
gen free con- described which also contains very high concentrations of
luced growth PGR despite virutally undetectable ER (Horwitz et al., 1982).
Progestins down regulate PGR in these cells by a combina-
0 tion of increased receptor degradation and decreased rate of
A^ synthesis (Nardulli et al., 1988). MPA induced down regula-
tion of PGR is also apparent in ZR-PR-LT cells (Table I).
Proliferation of ZR-PR-LT cells is inhibited by 4-hydroxy
tamoxifen despite loss of binding sites characteristic of type 1
ER. There is considerable evidence that anti-oestrogens and
E2 induce different conformational changes in ER (Hansen &
Gorski, 1986) and it has been suggested that different ligand
binding domains may be involved (Martin et al., 1988). The
ability of anti-oestrogens to inhibit the proliferation of breast
cancer cells adapted to growth in the apparent absence of
oestrogens has been consistently observed (Katzenellenbogen
et al., 1987; Welshons et al., 1987) and supports the proposal
that anti-oestrogens should be considered as receptor
proliferation targeted drugs (Rochefort, 1987). pEl (10-9M). Failure of E2 to reverse the growth inhibitory effects of
; , (10- M 4-hydroxy tamoxifen in ZR-PR-LT cells would be expected,
AM + E2; O but at present we have no explanation for the observation
that E2 (10' M) causes a slight increase in the anti-
proliferative effects of 4-hydroxy tamoxifen (Figure 5). Pro-
gestins are effective agents in the treatment of breast cancer,
but their mechanism of action is poorly understood. In vitro,
progestins show inconsistent effects on breast cancer cell
proliferation (Manni et al., 1987; Braunsberg et al., 1987).
T Although PGR is believed to be important in mediating the
0 anti-proliferative effects of progestins (Schneider et al., 1989)
other mechanisms may be involved, including interaction
\\o with the glucocorticoid receptor (Braunsberg et al., 1987).
\ We show that MPA is growth inhibitory towards ZR-75-1
s ^ cells growing in complete medium (Figure 6). In the short-
term absence ofoestrogenic activity, however, low concentra-
tions of MPA are growth stimulatory despite the absence of
detectable PGR. These results are in agreement with an
lo'-, 10'6 earlier report using T-47D human breast cancer cells (Hissom
& Moore, 1987), but the mechanism remains unclear. ZR-
n deprivation PR-LT cells revert to sensitivity to growth inhibition by
A. Values are MPA, but are only marginally more sensitive than ZR-75-1
Cell number cells despite expressing a 20-fold higher basal level of PGR
R-PR 5 days; (Table I). This suggests either that only minimal receptor
occupancy is required in order to elicit a maximal response,
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or that MPA is exerting its anti-proliferative effects through
a mechanism distinct from PGR. A poor correlation between
PGR concentration and response to progestins has been
observed previously (Braunsberg et al., 1987; Reddel et al.,
1988). Our data confirm that acquisition of oestrogen
independence does not necessarily imply anti-oestrogen resis-
tance in human breast cancer cells in culture, but it remains
to be established whether the selective pressure of complete
oestrogen deprivation occurs in vivo. Nevertheless, the steroid
hormone receptor profile and hormone sensitivity of ZR-PR-
LT cells raise important questions concerning the
mechanisms of action of anti-oestrogens and progestins in
human breast cancer.
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